MeiraGTx Holdings plc (MGTX)Healthcare | Biotechnology | New York, United States | NasdaqGS
13.82 USD
-0.32
(-2.263%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 13.82 |
Hot Take ↕ | Aug. 22, 2026, 4:09 a.m. EDT
The long-term outlook is solidified by exceptional fundamentals: revenue growth of +86%, operating margins near 76%, and a fortress balance sheet with a current ratio of 3.76. Despite a multi-year price decline, the business quality has clearly improved, evidenced by the sharp recovery in the trailing twelve months and a positive year-over-year direction. However, the short-term chart presents a distinct headwind; the stock is trading well above its 50-day average, creating immediate resistance, and the options market is screaming caution with heavy put buying. The disconnect between the pristine financials and the bearish options flow suggests the market is pricing in a binary event or regulatory hurdle. Until that risk resolves, the momentum remains negative despite the superior underlying economics. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.107909 |
| MSTL | 0.110607 |
| AutoETS | 0.123833 |
| AutoARIMA | 0.123834 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 1.52 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.220 |
| Excess Kurtosis | -1.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 52.053 |
| Revenue per Share | 4.748 |
| Market Cap | 1,327,314,176 |
| Trailing P/E | 16.26 |
| Forward P/E | -9.94 |
| Beta | 1.26 |
| Profit Margins | 19.87% |
| Website | https://www.meiragtx.com |
As of Aug. 22, 2026, 4:09 a.m. EDT: Speculators are heavily positioned for downside protection with significant out-of-the-money put open interest concentrated in the October expiration, while call activity remains sparse and focused near the money. This asymmetry suggests a market expectation of volatility or a specific catalyst-driven drop rather than a broad-based rally.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9369863 |
| Address1 | 655 Third Avenue |
| Address2 | Suite 1115 |
| All Time High | 30.23 |
| All Time Low | 3.49 |
| Ask | 17.57 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 812,760 |
| Average Daily Volume3 Month | 838,016 |
| Average Volume | 838,016 |
| Average Volume10Days | 812,760 |
| Beta | 1.255 |
| Bid | 13.85 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 2.289 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.82 |
| Current Ratio | 3.758 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 14.09 |
| Day Low | 13.65 |
| Debt To Equity | 52.053 |
| Display Name | MeiraGTx |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,794,486,600 |
| Earnings Timestamp Start | 1,794,486,600 |
| Ebitda | 196,131,008 |
| Ebitda Margins | 0.49341 |
| Enterprise To Ebitda | 6.611 |
| Enterprise To Revenue | 3.262 |
| Enterprise Value | 1,296,678,144 |
| Eps Current Year | 0.51 |
| Eps Forward | -1.39 |
| Eps Trailing Twelve Months | 0.85 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.8638 |
| Fifty Day Average Change | 0.95619965 |
| Fifty Day Average Change Percent | 0.074332595 |
| Fifty Two Week Change Percent | 93.69863 |
| Fifty Two Week High | 15.35 |
| Fifty Two Week High Change | -1.5300007 |
| Fifty Two Week High Change Percent | -0.09967431 |
| Fifty Two Week Low | 6.62 |
| Fifty Two Week Low Change | 7.2 |
| Fifty Two Week Low Change Percent | 1.0876132 |
| Fifty Two Week Range | 6.62 - 15.35 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,528,464,600,000 |
| Float Shares | 53,745,661 |
| Forward Eps | -1.39 |
| Forward P E | -9.942446 |
| Free Cashflow | 56,421,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 393 |
| Fullday Change | -0.320001 |
| Fullday Change Percent | -2.26309 |
| Fullday Price | 13.82 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.97949 |
| Gross Profits | 389,350,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16388 |
| Held Percent Institutions | 0.70425004 |
| Implied Shares Outstanding | 96,042,996 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York. |
| Long Name | MeiraGTx Holdings plc |
| Market | us_market |
| Market Cap | 1,327,314,176 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_404780252 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 78,982,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,357,087,533 |
| Number Of Analyst Opinions | 7 |
| Open | 13.93 |
| Operating Cashflow | 13,689,000 |
| Operating Margins | 0.76042 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 646 860 7985 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 13.82 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 14.14 |
| Price Eps Current Year | 27.09804 |
| Price Hint | 2 |
| Price To Book | 6.037571 |
| Price To Sales Trailing12 Months | 3.3391469 |
| Profit Margins | 0.19870001 |
| Quick Ratio | 3.226 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -0.320001 |
| Regular Market Change Percent | -2.26309 |
| Regular Market Day High | 14.09 |
| Regular Market Day Low | 13.65 |
| Regular Market Day Range | 13.65 - 14.09 |
| Regular Market Open | 13.93 |
| Regular Market Previous Close | 14.14 |
| Regular Market Price | 13.82 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 914,207 |
| Return On Assets | 0.38651 |
| Return On Equity | 0.72168 |
| Revenue Growth | 86.086 |
| Revenue Per Share | 4.748 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 96,042,996 |
| Shares Percent Shares Out | 0.038900003 |
| Shares Short | 3,738,795 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,215,627 |
| Short Name | MeiraGTx Holdings plc |
| Short Percent Of Float | 0.0543 |
| Short Ratio | 7.27 |
| Source Interval | 15 |
| State | NY |
| Symbol | MGTX |
| Target High Price | 50.0 |
| Target Low Price | 19.0 |
| Target Mean Price | 29.42857 |
| Target Median Price | 27.0 |
| Total Cash | 143,166,000 |
| Total Cash Per Share | 1.491 |
| Total Debt | 112,321,000 |
| Total Revenue | 397,500,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.85 |
| Trailing P E | 16.258823 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.5516 |
| Two Hundred Day Average Change | 4.2683992 |
| Two Hundred Day Average Change Percent | 0.4468779 |
| Type Disp | Equity |
| Volume | 914,207 |
| Website | https://www.meiragtx.com |
| Zip | 10,017 |